Palisade Bio, Inc.
- PALI
- NASDAQ
- Biotechnology
- Biotech (GI Disorders)
- Clinical-Stage Drug
$1.36
Today −3.19%Quote Oct 19, 2026, 05:00 PM UTC
−17.06%over the last month
Max drawdown −20.6%From 1-month high −17.1%3 months −26.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
14
Founded
2001
Market value
$237.9M
Quote Oct 19
Floor
$1.31
4.3% below price
Resistance
$1.37
0.3% above price
Price vs analyst targets
4 analysts
Lowest target
$2.00Highest target
$7.00
$2.00Highest target
$7.00
- Price $1.36
- Average target $4.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 230% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PALIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free